For patients with metastatic uveal melanoma, what are the treatment options? Marlana M. Orloff, M.D.: Metastatic uveal melanoma is unique in that when patients recur, close to 90% or more recur in ...

Delcath Systems (DCTH) announced the publication of a retrospective study by leading interventional radiologists and oncologists from Asklepios ...

In this study, researchers explored disparities in metastatic cutaneous melanoma survival following the introduction of immunotherapies.

What advice do you have for patients and caregivers of those recently diagnosed with uveal melanoma? Marlana M. Orloff, M.D.: Because metastatic uveal melanoma is so rare, it’s very important that ...

LUND, SE / ACCESS Newswire / October 8, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) (STO:BINV), a biotech company focused on the discovery and development of novel and ...

Delcath Systems, Inc. (Nasdaq: DCTH), ("Delcath" or the "Company") an interventional oncology company focused on the ...

Hepzato Kit, FDA-approved for metastatic uveal melanoma liver treatment, shows strong early revenue ($10M in Q3, $13.7M expected in Q4) with surprising profitability. The disease affects ~1,700 ...

WOBURN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today ...

Avelumab as second-line or later (2L+) treatment in patients (pts) with metastatic Merkel cell carcinoma (mMCC): Analysis of real-world outcomes in France using the CARADERM registry and the French ...

Credit: Shutterstock. Hepzato Kit is supplied with the Hepzato 5x5 Drug Pack and the HDS; it is expected to be available in the fourth quarter of 2023. The Food and Drug Administration (FDA) has ...

Please provide your email address to receive an email when new articles are posted on . The regional treatment conferred a significantly higher overall response rate than best alternative care. Median ...

The narrative review synthesizes data from prospective and retrospective studies from leading centers in the US and Europe, collectively demonstrating objective response rates of 36%-72%, median ...